PubMed Health⌕ Search

Biomedical subjects

B E García

Publications and source records attributed to B E García.

At least 37 records · Page 2Linked to original sources

A prospective safety-monitoring study of immunotherapy with biologically standardized extracts.

We evaluated the safety of immunotherapy in 419 patients who attended our allergy department for treatment. They were suffering from rhinitis and asthma caused by sensitization to grass pollen or Dermatophagoides pteronyssinus. Immunotherapy was given by biologically standardized aluminum hydroxide adsorbed extracts according to a conventional schedule. Local reactions were recorded in 10.5% of the patients and systemic reactions in 4.8%. Only 0.37% of the doses administered were associated with systemic side-effects. We found that 84% of the patients who showed systemic reactions were asthmatic subjects (P < 0.01), and most of them were sensitized to D. pteronyssinus (71%). Side-effects occurred more frequently during the dose-increase period (P < 0.05). After 9482 doses had been administered, no anaphylactic shock or life-threatening reactions were registered. We believe the risk associated with immunotherapy to be drastically reduced when treatment is carefully monitored by skilled personnel. In such conditions, as shown by our study, immunotherapy is safe.

Adult↗

Number of beta-receptors in patients allergic to Dermatophagoides pteronyssinus.

This study was carried out on 96 atopic patients with monosensitization against Dermatophagoides pteronyssinus and 30 control individuals. The patients were divided into 3 subgroups: 27 asymptomatic patients, 27 patients who only presented nasal symptomatology, and 27 patients with marked bronchial symptomatology. Total serum IgE, antigen-specific histamine release, and the number of beta 2-adrenergic receptors in peripheral blood lymphocytes in all patients were determined. The control group presented the highest number of beta-receptors in comparison with the bronchial symptomatic and nasal symptomatic patients. However, asymptomatic patients presented numbers of beta-receptors similar to controls, with no significant differences between both groups. No significant correlation was found between beta-adrenergic receptors and levels of total serum IgE. On the other hand, correlation between beta-receptors and specific histamine release was detected only in symptomatic nasal patients. It can be postulated that the decrease in beta-receptors is a consequence, and not the cause, of atopy.

Adult↗

Number of beta-receptors in rhinitic pollinic patients.

The study was carried out on venous blood from 67 patients with seasonal rhinoconjunctivitis caused by sensitization to grass pollen and 30 control individuals. Total IgE determination, antigen-specific histamine release test against two concentrations of Phleum pratense, and quantification of beta 2-adrenergic receptor numbers in lymphocyte membrane of peripheral blood were done on all patients. Those pollinic patients who were asymptomatic at the time of the study had 500.07 +/- 237.27 receptors/cell; no significant differences were established with the control group, with 541.53 +/- 123.63 receptors/cell. However, both the control group and asymptomatic patients had receptor numbers which were significantly higher than those of symptomatic pollinic patients, with 376.81 +/- 158.65 receptors/cell (p < 0.01 and p < 0.05, respectively). The average decrease in number of receptors in symptomatic pollinic patients was 30.42% in relation to controls and 24.65% in relation to asymptomatic patients. Within the subgroup of pollinic patients, studied both in and out of season, the number of beta 2-adrenergic receptors had an average decrease of 13.22% during pollination, with 363.7 receptors/cell. Once the pollination season was over, this figure increased to 419.1 receptors/cell, establishing significant differences with p < 0.025. The number of beta 2-adrenergic receptors did not correlate with total seric IgE figures or with antigen-specific histamine release. These data indicate that the decrease of these receptors does not constitute the causal factor of atopic diseases; it seems more likely to be a consequence of the same.

Adolescent↗

Study of IgE-dependent basophil releasability in allergic patients.

For this study, venous blood from 160 patients with a diagnosis of asthma and/or rhinitis was used. Histamine release test (H.R.T.) with anti-IgE at 1/5 and 1/25 dilutions and with causal antigen in the case of atopic patients (144) was carried out on all patients. Basophils from atopic patients released more histamine than those from nonatopic patients (p < 0.001). Basophils of atopic patients released more histamine with 1/5 anti-IgE dilution (p < 0.01), while non-atopic patients did so with the 1/25 dilution (p < 0.05). On grouping atopic patients according to positive or negative results in Ag-specific histamine release, 14% of patients presented negative Ag-specific H.R.T. and 85.7% of the cases did not respond to anti-IgE stimulus; this was 12% of the total number of atopics. On the other hand, 17% of the patients studied did not show positive histamine release against anti-IgE and 70.6% of them had negative Ag-specific release. As for the effect of age on IgE-dependent histamine release, the group of patients who presented greater releasability corresponded to those older than 6 years of age. The discrepancies observed between the clinical history, skin tests, serum IgE and antigen-dependent histamine release in some patients could be related to the individual basophil ability to release histamine. Therefore, this basophil releasability evaluation has an important practical application in discerning false negatives in antigen-specific H.R.T.

Adolescent↗

Results of the in vitro follow-up of immunotherapy.

With the advances made in allergological diagnosis, thanks to the application of various in vitro immunological techniques, we have also learnt more about the immunological modifications produced during the course of the immunotherapy. Among the techniques which will detect immunological changes is the histamine release test, which will show a decrease in antigen-specific histamine release. On the other hand, both total IgE and IgG4 are modified in the course of this immunotherapeutic treatment.

Follow-Up Studies↗

[The study of the inflammation of the airway in bronchial asthma by cytological and chemical analysis in the fluid phase of samples taken by sputum induction].

In recent years the study of samples of bronchial biopsies and bronchoalveolar lavage fluid has made it possible to show the existence of significant airway mucosal inflammation, even in cases of mild bronchial asthma. This has led to a renewed interest in the use of sputum to assess airway inflammation non-invasively. Sputum induction has recently been proposed as a non-invasive alternative to bronchoscopy for the collection of airway secretions from asthmatic subjects. Sputum induction yields satisfactory samples of sputum in the great majority of asthmatic subjects, and both differential cell counts and the measurement of molecular markers of inflammation in the sputum fluid phase are feasible. In this paper we review studies where these measurements have been taken from subjects who were asthmatic, affected by other respiratory pathologies or healthy, and we assess their validity. Finally, we consider possible future clinical applications of sputum measurement of airway inflammation in asthma.

English Abstract↗

Long-term immunotherapy with an optimal maintenance dose of a standardized Dermatophagoides pteronyssinus extract in asthmatic patients.

In a previous dose-titration study of specific immunotherapy (SIT) with a Dermatophagoides pteronyssinus extract in asthmatic patients, we proposed a dose of 3.2 micrograms of Der p and 1/1.6 micrograms of Der p 2 as an optimal maintenance dose. Changes presented by a high-dose immunotherapy group, with a maximum tolerated dose between 4 and 16 micrograms Der p 1, were compared with those of a conventional immunotherapy group, with a maximum tolerated dose of 3.2 micrograms Der p 1 or lower. After 2 years of SIT, both groups achieved the same level of clinical benefit. We now present the results of long-term monitoring of 25 of these patients, covering the 5 years of SIT in which the maintenance dose was set at 3.2 micrograms Der p 1. The aims of the study were firstly to examine if this maintenance dose could sustain the changes induced by immunotherapy in the first 2 years; and secondly, to determine if this dose is clinically effective in patients known to tolerate higher maintenance doses. The clinical severity index (CSI), medication and symptom scores, cutaneous sensitivity and specific IgE and IgG4 to D. pteronyssinus, Der p 1 and Der p 2 were measured. Positive clinical and immunological changes presented in the first 2 years of SIT were sustained (CSI, medication score, specific IgE) or even increased (symptom score, cutaneous sensitivity) after 3 additional years of SIT. In conclusion, a maintenance dose of 3.2 micrograms of Der p 1/1.6 micrograms of Der p 2 induced intense clinical and immunological changes which were sustained during a 5-year course of treatment, even in patients able to tolerate higher doses.

Adolescent↗

Cluster versus conventional immunotherapy in patients allergic to Dermatophagoides pteronyssinus: a controlled study of in vivo and in vitro parameters.

We designed a cluster schedule of immunotherapy for patients allergic to Dermatophagoides pteronyssinus which showed good safety and clinical efficacy. Here we compare the in vivo and in vitro changes with those of a conventional schedule in a controlled trial. Sixty-three patients were randomized as follows: 29 were treated with the cluster schedule, 15 with a conventional schedule and 19 received no immunotherapy. A standardized extract was used. Changes in in vivo parameters (skin prick test and conjunctival provocation test) and in in vitro parameters (IgE, IgG, IgG1 and IgG4 for the complete extract, Der p 1 and Der p 2) were measured before immunotherapy (T0), on reaching maintenance phase (T1), and after 6 (T2), 12 (T3) and 18 months of maintenance (T4). Cutaneous reactivity showed a significant decrease from T1 in both the cluster and conventional schedules, and conjunctival reactivity was also significantly lowered from T1 in these groups. Specific IgE decreased and specific IgG, IgG1 and IgG4 increased significantly from T1 in the cluster and conventional schedules. Neither of these parameters showed any changes in the group without immunotherapy. In conclusion, our cluster schedule induced changes in cutaneous and conjunctival reactivity and in immunological parameters that were similar to those achieved with the conventional schedule; these changes did not appear in patients who did not undergo immunotherapy.

Adolescent↗

Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy.

We designed a cluster schedule of immunotherapy for patients allergic to Dermatophagoides pteronyssinus to reach the maximal recommended dose in 7 weeks. We compared its safety and clinical efficacy with those of a conventional schedule in a controlled trial. Sixty-three patients were randomized as follows: 29 were treated with the cluster schedule, 15 with a conventional schedule and 19 without immunotherapy. A standardized extract was used. Clinical efficacy was measured by visual analog scale, clinical severity score, symptom/medication diary cards and control of peak expiratory flow (PEF) in asthmatic patients, before immunotherapy (T0), on reaching the maintenance phase (T1), and after 6 (T2), 12 (T3) and 18 months of maintenance (T4). The safety of immunotherapy was found to be good. Visual analog scale improved significantly at T4 in the cluster and conventional schedules, and clinical severity score also improved from T1 in these schedules. Diary cards improved from T1 in the cluster schedule and from T2 in the conventional schedule in asthmatic patients. Significant improvements in diary cards in rhinitis patients and PEF were found only in the cluster schedule. There were no changes in the group without immunotherapy. In conclusion, our cluster schedule showed as good tolerance and clinical efficacy as the conventional schedule in patients allergic to D. pteronyssinus. These clinical improvements did not appear in the group without immunotherapy.

Adolescent↗

Tolerance of immunotherapy with a standardized extract of Alternaria tenuis in patients with rhinitis and bronchial asthma.

We studied the safety of immunotherapy with an Alternaria extract in patients with rhinitis and bronchial asthma. The few studies that have investigated immunotherapy with mold allergens suggest that they cause adverse reactions more frequently than do other extracts. All treatments prescribed by our allergology service with Alternaria immunotherapy between 1988 and 1996 were recorded and analyzed. In all cases a biologically standardized depot extract of Alternaria tenuis containing 5 BU/ml was used according to a conventional immunotherapy schedule. During the study period 129 patients received immunotherapy with Alternaria extract. Of the 3,892 doses given, 1.95% led to adverse reactions, which occurred in 39.5% of the patients. Most of the adverse reactions were systemic and mild, and reproduced the underlying disease. The risk of adverse reactions was significantly higher in children, patients with asthma, and during the initial phase of treatment. Patients who suffered from adverse reactions had a significantly higher level of total and specific IgE. It was concluded that tolerance of Alternaria mold extract was worse than for other allergenic extracts, although most reactions recorded were mild. The risk of adverse reactions was greater in children and patients with asthma, and during the initial phase of immunotherapy.

Adolescent↗

Specific IgG subclasses in pollinosis.

We studied IgG subclasses in pollinosis in order to determine the possible immunopathological role of these antibodies, especially antigen-specific IgG4. The selection of pollinosic patients allowed us to observe the influence natural antigenic exposure exerts upon antibodies. On the other hand, we intended to study the possible modifications immunotherapy produces on IgG subclasses. For this purpose, we selected 266 patients who were classified into the following groups: Group I, 65 patients without immunotherapy, 35 of whom were studied during the pollen season and 30 outside the pollen season; Group II, 40 nonpollinosic patients with hypersensitization to Dermatophagoides pteronyssinus were taken as atopic controls; Group III, 161 pollinosic patients with from 3 to 42 months of immunotherapy. For every patient, IgG1, IgG2 and IgG3 against Phleum pratense were determined by means of ELAST (Leti), and IgG4 against the same allergen by means of the ELISA technique developed by us. Our results confirm, first, that untreated pollinosic patients present higher concentrations of IgG4 against Phleum than nonpollinosic patients, and second, that immunotherapy produces significant modifications in the production of antigen-specific IgG.

Antibody Specificity↗

Effect of ketotifen on phosphodiesterase activity from asthmatic individuals.

It was demonstrated, in this study, that phosphodiesterase activity was elevated in asthmatic patients compared to healthy individuals. This may be reason why various authors found higher intracellular cAMP levels in healthy individuals than in asthmatic patients. We also demonstrated that the efficacy of ketotifen in inhibiting antigen-specific histamine release is due to the potent inhibitor effect of ketotifen on cellular phosphodiesterase activity which then allowed intracellular cAMP accumulation, and as a consequence prevented mediators release.

3',5'-Cyclic-AMP Phosphodiesterases↗

Decrease of beta-receptors after the antigen-specific bronchial provocation test in bronchial asthma.

Airway hyperreactivity to different stimuli is a characteristic feature of bronchial asthma. The beta-adrenergic theory, as proposed by Szentivanyi in 1968, tried to explain with beta-adrenergic dysfunction, the cause not only of bronchial hyperreactivity but of all atopic diseases. In a previous work, we found that asymptomatic asthmatic patients presented a number of beta-receptors similar to that of a normal control group, while symptomatic asthmatic patients presented a significantly decreased number when compared to both groups (40% decrease). In view of these results, we proposed to study the possible changes in the number of beta-receptors in asymptomatic asthmatic patients after a bronchial provocation test. Fifteen patients, diagnosed of bronchial asthma and sensitive to the house dust mite, D. pteronyssinus, were studied. All were free of medication and asymptomatic at least 90 days before the study. A test of specific bronchial provocation was performed on 10 patients, determining the number of beta-receptors in basal conditions, after 30 minutes and 24 hours. The other five patients underwent an unspecific provocation test with methacholine, with determination of the beta-receptor number at basal conditions, and 24 hours later. Only a significant decrease (30.4%) was found in the beta-receptor numbers, 24 hours after specific bronchial provocation with p less than 0.025 with the Student test for paired data. With regards the beta-adrenergic theory of atopy, in our opinion our results show that the detected decrease of beta-receptors would be the consequence and not the cause of atopic diseases.

Allergens↗

Value of IgG4 antibodies against foods in atopic dermatitis.

Various authors have linked IgG4 antibodies to biological activities that are apparently contradictory in different studies. On one hand, it has been confirmed that during immunotherapy with inhalant and Hymenoptera venom antigens, an increase is produced in specific IgG4 levels. On the other hand, it has been suggested that these antibodies can intervene in hypersensitivity reactions, basically when these are directed against food antigens. We studied IgG4 levels against milk and egg fractions in patients with atopic dermatitis (AD) (n = 23), and in healthy individuals (n = 20). Patients with AD had significantly much higher IgG4 levels against egg white (24.16 micrograms/ml), egg yolk (9.96 micrograms/ml) and beta-lactoglobulin (10 micrograms/ml) than those found in healthy individuals (6.75, 3.12, 3.35 micrograms/ml, respectively), with no significant differences for alpha-lactalbumin and casein. Patients with AD without hypersensitivity to egg and milk, at the moment of the study, also had significantly higher levels than those of control individuals, against egg white (27.11 micrograms/ml), egg yolk (12 micrograms/ml) and beta-lactoglobulin (11.72 micrograms/ml). There were no differences in IgG4 levels against alpha-lactalbumin, beta-lactoglobulin and casein, when comparing patients with AD and hypersensitivity to milk, and patients with AD without present hypersensitivity to milk. We concluded that patients with AD presented high IgG4 levels against egg and milk fractions, in relation to the healthy population, and that the fraction of milk with the highest antigenic potency was beta-lactoglobulin.

Adolescent↗